Serum brain-derived neurotrophic factor following oral esketamine in treatment-resistant depression: Results from a randomized placebo-controlled trial.
Sara Massetti, Sanne Y Smith-Apeldoorn, Jolien K E Veraart, Jeanine Kamphuis, Anneke Muller Kobold, Eleni T. Tzavara, Peter Meerlo, Robert A Schoevers, Jens H van Dalfsen
Journal of Affective Disorders July 16, 2026 DOI: 10.1016/j.jad.2026.122265 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Randomized controlled trial Placebo-controlled Peer reviewed |
|---|---|
| Sample size | 54 |
| Population | Patients with treatment-resistant depression |
| Intervention | Esketamine |
| Dose | 90 mg/day, three 30 mg intakes |
| Duration | 6-week treatment, 4-week washout |
| Topics | Depression Esketamine Ketamine |
| Keywords | Brain-derived neurotrophic factor Clinical trial |
| Key findings | Repeated, low-dose, oral esketamine did not increase serum BDNF relative to placebo. |
Abstract
Ketamine and its enantiomer esketamine are efficacious in 30-35% of the patients with treatment-resistant depression (TRD). Increased serum brain-derived neurotrophic factor (BDNF) following treatment has been proposed as a potential biomarker of antidepressant response. This is based on studies evaluating single intravenous ketamine treatment. BDNF expression at different treatment schedules remains unclear. This study investigated the effects of daily, low-dose, oral (PO) esketamine on serum BDNF levels in TRD. Biomaterials were obtained from a randomized, placebo-controlled trial investigating six-week PO esketamine treatment (90 mg/day, three 30 mg intakes) that found no difference between conditions on the primary outcome (Hamilton Depression Rating Scale). Depression severity and serum BDNF levels were assessed in 54 patients at baseline, end of treatment, and after a four-week washout period. Repeated measures analyses of variance (ANOVA) were conducted to test the effect of treatment on depression severity and BDNF. Pearson's correlation analysis evaluated the association between changes in depression severity, ketamine metabolites and BDNF. The change in BDNF levels during treatment did not significantly differ between the esketamine and placebo group during treatment or washout. An increase in BDNF (F(1,50) = 4.606, p = 0.037) was found irrespective of treatment condition. In the esketamine arm, BDNF changes did not correlate with changes in depression severity, nor with metabolites levels. Repeated, low-dose, PO esketamine did not increase serum BDNF relative to placebo. While consistent with its limited clinical efficacy, it remains uncertain whether this reflects an unreached pharmacological threshold to engage synaptic plasticity.
Comparable studies
Other randomized controlled trials on esketamine for depression, most cited first.
Citations in the library
Cites 25
- A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression Archives of General Psychiatry August 1, 2006
- Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms Pharmacological Reviews June 26, 2018
- Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression JAMA Psychiatry June 5, 2019
- Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study American Journal of Psychiatry April 16, 2018
- Role of BDNF in the pathophysiology and treatment of depression: Activity‐dependent effects distinguish rapid‐acting antidepressants European Journal of Neuroscience December 6, 2019
and 20 more in the library